Infecciones asociadas a la atención de salud en pacientes pediátricos en terapia de sustitución renal y postrasplantados
Healthcare-associated infections in pediatric patients on renal replacement therapy and post-transplant patients
DOI:
https://doi.org/10.37910/RDP.2026.15.3.e469Keywords:
Healthcare-associated infections (HAIs), Pediatric kidney transplantation, Renal replacement therapy, Peritoneal dialysis, Hemodialysis, Morbidity, Mortality, ImmunosuppressionAbstract
Introduction: Healthcare-associated infections (HAIs) increase hospital stay and morbidity and mortality in immunosuppressed and post-transplant patients. Objective: To evaluate the etiology, risk factors, evolution, and treatment of HAIs in patients on renal replacement therapy and kidney transplant recipients with HAI events. Method: An observational, descriptive, cross-sectional, ambispective study was conducted with patients aged 1 month to 18 years hospitalized at the JM de los Ríos Children's Hospital from January 2025 to March 2026. Data were collected on demographic characteristics, type of infection, hospital stay, evolution, and treatment received; recorded in a database and analyzed using STATA-12 software, calculating relative frequencies, percentages for nominal variables, and measures of central tendency. Results: 108 patients were included, 60.19% (65/108) female, 39.81% (43/108) male, 46.30% (50/108) school-aged children, and 47.22% (51/108) adolescents. The main type of healthcare-associated infection (HAI) was bacteremia (44.44% (48/108)). There was a statistically significant association between age group and type of diagnosis, and there was also a difference in clinical course according to age group (Fisher's exact test, p < 0.001, statistically significant). Infants and preschoolers had a satisfactory outcome, while school-aged children had a poor outcome. Patients with Stage V Chronic Kidney Disease (94.74%) were the most affected; school-aged children and adolescents had a higher number of HAI events. There were 28 microbiological isolates, with E. coli and Klebsiella pneumoniae being the most frequent Gram-negative bacteria. Cefepime plus Vancomycin combinations predominated at 12.96% (14/108) and Meropenem plus Vancomycin at 11.11% (12/108). Conclusions: The outcome was either satisfactory or poor depending on the age group and the type of healthcare-associated infection (HAI). School-aged children and adolescents had a higher number of HAI events. Gram-negative microorganisms were the most frequently isolated, and antibiotic combinations were the most commonly prescribed treatments.
References
1. Vieira B, De Aguiar Y, Affonso F, Conceição L. Chronic kidney disease based on a database of health. Rev Assoc Med Bras. 2024;70(11):e20240644
2. Francis A, Shroff R, Earley A, Foster BJ. KDIGO 2024 Guidelines-Key Points for Pediatricians. JAMA Pediatr. 2025 Feb 1;179(2):114-116. doi: 10.1001/jamapediatrics.2024.5274. PMID: 39621318.
3. KDIGO 2023. Clinical practice guideline for the evaluation and management of chronic kidney disease. 2023. [cited on 2023 Jul 20]. Available from:https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2023-CKD-Guideline-Public-Review-Draft_5-July-2023.pdf
4. Dong SW, Sharma TS and Sue PK (2023) Approach to multidrug resistant infections in pediatric transplant recipients. Front. Pediatr. 11:1270564. doi: 10.3389/fped.2023.1270564
5. Van Mourik M, Perencevich E, Gastmeier P, Bonten M. Designing Surveillance of Healthcare-Associated Infections in the Era of Automation and Reporting Mandates. Clin Infect Dis. 2018 Mar 5;66(6):970-976. doi: 10.1093/cid/cix835.
6. Moralejo D, El Dib R, Prata RA, Barretti P, Corrêa. Improving adherence to Standard Precautions for the control of health care-associated infections. Cochrane Database Syst Rev. 2018 Feb 26;2:CD010768. doi: 10.1002/14651858.CD010768.pub2.
7. Haque M, Sartelli M, McKimm J, Muhamad Abu Bakar. Health care-associated infections – an overview. Infect Drug Resist. 2018; 11: 2321–2333. Published online 2018 Nov 15. doi: 10.2147/IDR.S177247
8. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. (2012) 18(3):268–81. doi: 10.1111/j.1469-0691.2011. 03570.x
9. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America antimicrobial-resistant treatment guidance: gram-negative bacterial infections. Infectious Diseases Society of America (2023). Available at: https://www.idsociety.org/practice-guideline/amr-guidance/ (Accessed July 16, 2023).
10. Bush K, Bradford PA. Epidemiology of β-lactamase-producing pathogens. Clin Microbiol Rev. (2020) 33(2):e00047–19. doi: 10.1128/CMR.00047-19
11. WHO-Global Health Observatory (GHO) Data; 2016. Geneva, Switzerland: World Health Organization Disponible en: https://www.who.int/gho/en/
12. Healthcare Infection Control Practices Advisory Committee. Antibiotic Stewardship Statement for Antibiotic Guidelines – The Recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC). 2016.
13. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013 Dec 9-23;173(22):2039-2046. doi: 10.1001/jamainternmed.2013.9763.
14. Henig O, Katz D, Marchaim D. (2018) Multidrug-Resistant Gram-Negative Bacilli: Infection Prevention Considerations. In: Bearman G., Munoz-Price S., Morgan D., Murthy R. (eds) Infection Prevention. Springer, Cham
15. Sood G., Leekha S. (2018) Controversies in Healthcare-Associated Infection Surveillance. In: Bearman G., Munoz-Price S., Morgan D., Murthy R. (eds) Infection Prevention. Springer, Cham
16. Logan LK, Renschler JP, Gandra S, Weinstein RA, Laxminarayan R; Centers for Disease Control; Prevention Epicenters Program. Carbapenem-resistant Enterobacteriaceae in children, United States, 1999-2012. Emerg Infect Dis. (2015) 21(11):2014–2021. doi: 10.3201/eid2111.150548
17. De Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA, et al. Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev. (2020) 33(3): e00181–19. doi: 10.1128/CMR.001
18. Boyce JM, Pittet D. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep. 2002 Oct 25; 51(RR-16):1-45, quiz CE1-4
19. Sax H, Allegranzi B, Uçkay I. “My five moments for hand hygiene” – a user-centred design approach to understand, train, monitor and report hand hygiene. Journal of Hospital Infection. 2007; 67:9-21.
20. Pittet D, Hugonnet S, Harbarth S.. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. University of Geneva, Switzerland. Lancet. 2000; 356(9238): 1307-1312.
21. W.-M. Zhao et al. Global, regional and national burden of CKD in children and adolescents from 1990 to 2019. Nephrol Dial Transplant, 2024, 39, 1268–1278 https://doi.org/10.1093/ndt/gfad269
22. Battagliaa T, Casartellia P, Muracab Ml. Timing of Renal Transplant in Survivor Children with Relapse of Wilms Tumor: A Case Series Study. Case Rep Oncol 2025;18:449–455 DOI: 10.1159/000543176
23. Gil Cunquero J.M. Infecciones ante la modalidad de diálisis. La realidad y la percepción de las infecciones en diálisis, Nefrologia 2010;1(Supl Ext 1):56-62.
24. Pisoni R. Vascular access use in Europe and the United States: Results from the DOPPS. Kidney Int 2002;61:305-316.
25. Gorriz JL, Sancho A, Pallardó LM, Amoedo ML, Martín M, Sanz P, et al. Significado pronóstico de la diálisis programada en pacientes que inician tratamiento sustitutivo renal. Un estudio multicéntrico español. Nefrologia 2002;22(1):49-59.
26. Oliver MJ, Callery SM, Thorpe KE, Schwab SJ, Churchil DN. Risk of bacteriemia from temporary hemodialysis catheters by site of insertion and duration of use: A prospective study. Kidney Int 2000;58:2543-2545.
27. Marrón B, Ortiz A, De Sequera P, Martín-Reyes G, De Arriba G, Lamas JM, et al.; Spanish Group for CKD. Impact of end-stage renal disease care in planned dialysis start and type of renal replacement therapy-a Spanish multicentre experience. Nephrol Dial Transplant 2006;21(Suppl 2):51-55.
28. Datos procedentes del Registro de la Sociedad Andaluza de Nefrología, 2006. 19. Oliver MJ, Callery SM, Thorpe KE, Schwab SJ, Churchil DN. Risk of bacteriemia from temporary hemodialysis catheters by site of insertion and duration of use: A prospective study. Kidney Int 2000;58:2543-2545.
29. Bajo MA, Selgas R. Plan de Calidad Científico Técnica y de Mejora Continua de Calidad en Diálisis Peritoneal. Sociedad Española de Nefrología. Disponible en: http://www.senefro.org/modules/subsection/files/calidad_dp__sen_2007.pdf
30. Kent JR, Almond MK. A survey of CAPD peritonitis management and outcomes in north and south thames NHS regions (U.K.): Support for the ISPD Guidelines. Perit Dial Int 2000;20:301-305.
31. Pérez-Fontán M, Rodríguez-Carmona A, García-Naveiro A, Rosales M, Villaverde P, Valdés F. Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int 2005;25:274-284.
32. Remón C, Quirós PL, Pérez-Bañasco V, Torán D, Tejuca F, Merino MJ, et al. Informe del registro de pacientes con insuficiencia renal crónica en tratamiento con diálisis peritoneal de Andalucía: período 1999-2004. Nefrologia 2006;26(1):45-55.
33. Sarnak MJ, Jaber BI. Pulmonar infectious mortality among patients with endstage renal disease. Chest 2001;120:1883-7. 33. Foley RN. Infections in Patients with Chronic Kidney Disease. Infect Dis Clin North Am 2007;21:659-672.
34. Guo H, Liu J, Collins AJ, Foley RN. Pneumonia in incident dialysis patients-the United States Renal Data System. Nephrol Dial Transplant 2008;23:68068-6.
35. Abbott KC, Agodoa LY. Hospitalizations for Bacterial Endocarditis after Initiation of Chronic Dialysis in the United States. Nephron 2002;91:203-209.
36. Doulton T, Sabharwal N, Cairns HS, Schelenz S, Eykyn S, O’Donnell P, et al. Infective endocarditis in dialysis patients: New challenges and old. Kidney Int 2007;64:720-727.
37. Kamalakannan D, Pai RM, Johnson LB, Gardin JM, Saravolatz LD. Epidemiology and Clinical Outcomes of Infective Endocarditis in Hemodialysis Patients. Ann Thorac Surg 2007;83:2081-2086
38. Johnson DW, Dent H, Yao Q, Tranaeus A, Huang C, Han D, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asian-Pacific countries: analysis of registry data. Nephrol Dial Transplant 2009;24:1598-1603.
39. USRDS Annual Data Report 2009. Volume two: Atlas of End-Stage Renal Disease in the United States and Volume 3: Reference Tables on End-Stage Renal Disease. Disponible en: http://www.usrds.org/adr.htm
40. Foley RN, Guo H, Snyder JJ, Gilbertson DT, Collins AJ. Septicemia in the United States Dialysis Population, 1991 to 1999. J Am Soc Nephrol 2004;15:1038-1045.
41. Chavers BM, Solid CA, Gilbertson DT, Collins AJ. Infection-Related Hospitalization Rates in Pediatric versus Adult Patients with End-Stage Renal Disease in the United States. J Am Soc Nephrol 2007;18:95295-9.
42. Aslam N, Bernardini J, Fried L, Burr R, Piraino B. Comparison of Infectious Complications between Incident Hemodialysis and Peritoneal Dialysis Patients. Clin J Am Soc Nephrol 2006;1:1226-1233.
43. Lopez Oliva María, Loeches Belén, Infecciones en el Trasplante Renal. En: Lorenzo V., López Gómez JM (Eds). Nefrología al día. ISSN: 2659-2606. Disponible en: https://www.nefrologiaaldia.org/280
44. Levin A, et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. doi: 10.1016/j.kint.2024.01.005.
45. Fariñas MC, García J, Gutiérrez M. Infecciones asociadas a los catéteres utilizados para la hemodiálisis y la diálisis peritoneal. Enferm Infecc Microbiol Clin 2008;26(8):518-526
46. Taylor G, Gravel D, Johnston L, Embil J, Holton D, Paton S. Incidence of bloodstream infection in multicenter inception cohorts of hemodialysis patients. Am J Infect Control. 2004;32:155-160.
47. Astor BC, Eustace JZ, Powe NR, Klag MJ, Fink NE, Coresh J. The CHOICE Study. Type of vascular access and survival among incident hemodialysis patients: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. J Am Soc Nephrol. 2005;16:1449-1455.
48. Perini S, LaBerge JM, Peral JM, Santiesteban HL, Ives HE, Omachi RS, et al. Tesio Catheter: Radiologically Guided Placement, Mechanica, Performance, and Adequacy of Delivered Dialysis. Radiology. 2000;215:129-137.
49. Di Iorio B. Central Venous Catheter in hemodialysis: an actual conundrum without solutions. J Vasc Access. 2002;3:174-176.
50. Butterly DW, Schwab SJ. Dialysis access infections. Curr Opin Nephrol Hypertens. 2000;9:631-635.
51. Oliver MJ, Callery SM, Thorpe KE, Schwab SJ, Churchill DN. Risk of bacteremia from temporary hemodialysis catheters by site of insertion and duration of use: a prospective study. Kidney Int. 2000;58:2543-5. Saad TF. Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis. 1999;34:1114-1124
52. Vila J, Soriano A, Mensa J. Molecular basis of microbial adherence to prosthetic materials. Role of biofilms in prosthesis-associated infection. Enferm Infecc Microbiol Clin. 2008;26:48-54.
53. Humar A, Ostromecki A, Direnfeld J, Marshall JC, Lazar N, Houston PC, et al. Prospective randomized trial of 10% povidone-iodine versus 0.5% tincture of chlorhexidine as cutaneous antisepsis for prevention of central venous catheter infection. Clin Infect Dis. 2000;31:1001-1007.
54. Fariñas MC, García-Palomo JD, Gutiérrez-Cuadra M. Infecciones asociadas a catéteres utilizados para la hemodiálisis y la diálisis peritoneal. Enferm Infecc Microbiol Clin 2008;26(8):518-526
55. Merzkani et al. Immunotherapy and Cellular Therapies for Cancers in Kidney Transplant Patients. Am J Nephrol. DOI: 10.1159/000544826
56. Ranawaka R, Dayasiri K, Sandamali E, Gamage M. Management strategies for common viral infections in pediatric renal transplant recipients. World J Transplant. 2024 Mar 18;14(1):89978. doi: 10.5500/wjt.v14.i1.89978. PMID: 38576764; PMCID: PMC10989477.
57. Nguyen DB, Arduino MJ, Patel PR. Hemodialysis-Associated Infections. Chronic Kidney Disease, Dialysis, and Transplantation. 2019:389–410.e8. doi: 10.1016/B978-0-323-52978-5.00025-2. Epub 2018 Nov 29. PMCID: PMC7152337.
58. Asociación Médica Mundial. Declaración de Helsinki de la AMM: Principios éticos para las investigaciones médicas en seres humanos. Ferney-Voltaire, Francia: AMM; 2024. Disponible en: https://www.directa.it/help-supporto/conto-directa/guida-apertura-conto-directa.
59. Gutiérrez G, Galeano F, Florentín de Merech L. Infectious complications in pediatric kidney transplants. Rev. Inst. Med. Trop 2023; 18(2):28-36
60. Florentín de Merech L, Flores J, Ferraris J. Guia de Trasplante Renal Pediatrico. Efacim 2018.
61. North American Pediatric Renal Trials and Collaborative Studies: 2014 Annual Report. Disponible en: http://www.naprtcs.org/ Página web visitada el 06-Mar- 2016.
62. Matoses ML, Fernández Camblor C. Trasplante renal en Pediatría. Protoc diagn ter pediatr. 2022; 1:493-508.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Lisbeth Aurenty

This work is licensed under a Creative Commons Attribution 4.0 International License.
Usted es libre de:
- Compartir — copiar y redistribuir el material en cualquier medio o formato
- Adaptar — remezclar, transformar y construir a partir del material
- para cualquier propósito, incluso comercialmente.
Bajo los siguientes términos:
-
Atribución — Usted debe dar crédito de manera adecuada, brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
- No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.







